One-Year Results of Aflibercept in Vascularized Pigment Epithelium Detachment due to Neovascular AMD: A Prospective Study

Abstract

Purpose

To evaluate individualized intravitreal aflibercept regimens for treatment of neovascular age-related macular degeneration (nAMD)-related pigment epithelial detachment (PED).

Methods

This prospective, multicenter, nonrandomized study included 32 eyes with nAMD-related PED, treated with ranibizumab for ≥6 months. All patients received intravitreal aflibercept (2 mg/0.05 mL) at baseline (no loading phase) and subsequently treated pro re nata with monthly follow-up for 12 months. Outcome measures included visual acuity, central retinal thickness (CRT), PED height and area, and neovascular network size.

Results

At 12 months, aflibercept improved mean best-corrected visual acuity compared with baseline values (p>0.05); 50% of patients displayed complete resolution of intraretinal and/or subretinal fluid. Compared with baseline, significant decreases were observed for mean CRT and PED height (both p<0.01).

Conclusions

Aflibercept appears to induce anatomical improvement for at least 12 months after conversion from ranibizumab in patients experiencing nAMD-related PED. Significant reductions in both mean PED height and CRT were observed, although these changes were not necessarily related to significantly improved visual acuity scores. However, larger patient cohorts are required to extend and validate our results, and increased study duration would allow exploration of the potential long-term benefits and challenges of prolonged aflibercept use.

Keywords

Aflibercept Anti-VEGF Neovascular age-related macular degeneration Pigment epithelium detachment

Get full access to this article

View all access options for this article.

References

Ferrone

Anwar

Naysan

et al. Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration. Br J Ophthalmol 2014;98 Suppl 1i17–i21

Coscas

Souied

Tick

Soubrane

Optical coherence tomography identification of occult choroidal neovascularization in age-related macular degeneration.

Am J Ophthalmol 2007;144 (4):592–599

Pauleikhoff

Löffert

Spital

et al. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol 2002;240 (7):533–538

Yuzawa

Fujita

Wittrup-Jensen

et al. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration. Ophthalmology 2015;122 (3):571–578

Schmidt-Erfurth

Kaiser

Korobelnik

et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014;121 (1):193–201

Singer

Awh

Sadda

et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012;119 (6):1175–1183

Martin

Maguire

Ying

Grunwald

Fine

Jaffe

CATT Research Group.

Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364 (20):1897–1908

Holz

Amoaku

Donate

et al;

SUSTAIN Study Group.

Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011;118 (4):663–671

Schmidt-Erfurth

Eldem

Guymer

et al;

EXCITE Study Group.

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011;118 (5):831–839

10.

Boyer

Heier

Brown

Francom

Ianchulev

Rubio

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.

Ophthalmology 2009;116 (9):1731–1739

11.

Brown

Michels

Kaiser

Heier

Ianchulev

ANCHOR Study Group.

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116 (1):57–65.e5

12.

Lalwani

Rosenfeld

Fung

et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148 (1):43–58.e1

13.

Regillo

Brown

Abraham

et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145 (2):239–248

14.

Fung

Lalwani

Rosenfeld

et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143 (4):566–583

15.

Rosenfeld

Brown

Heier

et al;

MARINA Study Group.

Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355 (14):1419–1431

16.

Yüksel

Türkcü

Sahin

et al. One year results of anti-VEGF treatment in pigment epithelial detachment secondary to macular degeneration. Arq Bras Oftalmol 2013;76 (4):209–211

17.

Introini

Torres

Gimeno A

Scotti

Setaccioli

Giatsidis

Bandello

Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence.

Graefes Arch Clin Exp Ophthalmol 2012;250 (9):1283–1292

18.

Arora

McKibbin

One-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degeneration.

Eye (Lond) 2011;25 (8):1034–1038

19.

Arias

Treatment of retinal pigment epithelial detachment with antiangiogenic therapy.

Clin Ophthalmol 2010;4369–374

20.

Ritter

Bolz

Sacu

et al. Effect of intravitreal ranibizumab in avascular pigment epithelial detachment. Eye (Lond) 2010;24 (6):962–968

21.

Lommatzsch

Heimes

Gutfleisch

Spital

Zeimer

Pauleikhoff

Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments.

Eye (Lond) 2009;23 (12):2163–2168

22.

Papadopoulos

Martin

Ruan

et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15 (2):171–185

23.

Batioglu

Demirel

Özmert

Abdullayev

Bilici

Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD.

BMC Ophthalmol 2015;1540

24.

Broadhead

Hong

Zhu

et al. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration. Retina 2015;35 (5):975–981

25.

Chan

Jain

Sadda

Varshney

Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).

Trans Am Ophthalmol Soc 2014;112160–98

26.

Fassnacht-Riederle

Becker

Graf

Michels

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD.

Graefes Arch Clin Exp Ophthalmol 2014;252 (11):1705–1709

27.

Gharbiya

Iannetti

Parisi

De Vico

Mungo

Marenco

Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.

Biomed Res Int 2014;2014273754

28.

Grewal

Gill

Sarezky

Lyon

Mirza

Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results.

Eye (Lond) 2014;28 (7):895–899

29.

Thorell

Nunes

Chen

et al. Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD. Ophthalmic Surg Lasers Imaging Retina 2014;45 (6):526–533

30.

Ziegler

Heimes

Book

et al. [Change of therapy from ranibizumab to aflibercept for recurrent or persistent exudative age-related macular degeneration]. Ophthalmologe 2015;112 (5):435–443

31.

Kumar

Marsiglia

Mrejen

et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013;33 (8):1605–1612

32.

Silva

Moshfeghi

Blumenkranz

Leng

Aflibercept for the treatment of retinal pigment epithelial detachment.

Retina 2016;36 (3):492–498

33.

Patel

Chow

Rathod

et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye (Lond) 2013;27 (5):663–667 quiz 668.

34.

Singh

Srivastava

Ehlers

et al. A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis. Clin Ophthalmol 2015;91759–1766

35.

Spaide

Ranibizumab according to need: a treatment for age-related macular degeneration.

Am J Ophthalmol 2007 143 (4):679–680

36.

Engelbert

Zweifel

Freund

“Treat and extend” dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation.

Retina 2009;29 (10):1424–1431

37.

Engelbert

Zweifel

Freund

Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified “treat and extend” dosing regimen of intravitreal antivascular endothelial growth factor therapy.

Retina 2010;30 (9):1368–1375

38.

Golbaz

Ahlers

Stock

et al. Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy. Invest Ophthalmol Vis Sci 2011;52 (3):1599–1605